It looks like Novartis spent $3.5 billion dollars to buy a company that manufactures specialized treatments.
I'm old enough to remember when they spent $9 billion dollars on a company that manufactures specialized treatments, and they immediately drove the division off a cliff.
Hired clueless, incompetent retreads to run things, did not invest in sales data, did not invest appropriately in acquisition channels, tried to give the product away to cover-up for their abysmal sales numbers, and fired all the systems of care teams after fifteen months to try to save a few bucks.
Here is a thought: since Duane, Vicky, Sandeep and Jeff have done such a remarkable job with Leqvio, why not bring them over and have them launch the Chinook products?
What could go wrong? Novartis clearly has confidence in these buffoons; after all, they are still here. Since they knocked Leqvio out of the park, why not hand them the next billion-dollar compound and let them achieve the same level of success they have in the ASCVD space?
I'm old enough to remember when they spent $9 billion dollars on a company that manufactures specialized treatments, and they immediately drove the division off a cliff.
Hired clueless, incompetent retreads to run things, did not invest in sales data, did not invest appropriately in acquisition channels, tried to give the product away to cover-up for their abysmal sales numbers, and fired all the systems of care teams after fifteen months to try to save a few bucks.
Here is a thought: since Duane, Vicky, Sandeep and Jeff have done such a remarkable job with Leqvio, why not bring them over and have them launch the Chinook products?
What could go wrong? Novartis clearly has confidence in these buffoons; after all, they are still here. Since they knocked Leqvio out of the park, why not hand them the next billion-dollar compound and let them achieve the same level of success they have in the ASCVD space?